All data presented is sourced from publicly available scientific literature. No personal experience or testimonial is implied.
An FDA advisory panel vote on March 5, 2025, has shifted the landscape for compounded peptide access. The panel voted 14-0 that tirzepatide no longer appears on the FDA shortage list, a decision that could end bulk compounding of the drug within months. This vote does not directly affect semaglutide, which remains in shortage, but it signals a broader regulatory tightening. Researchers tracking GLP-1 receptor agonists will need to watch enforcement timelines, pharmacy compliance, and ongoing safety warnings from the agency.
The March 2025 Advisory Panel Vote
The FDA's Pharmacy Compounding Advisory Committee reviewed updated drug shortage data. Tirzepatide, sold as Mounjaro and Zepbound, was declared available in all presentations. The panel's unanimous vote is not binding, but the FDA typically follows such recommendations. A final decision is expected by late March 2025. If the agency concurs, compounders must stop producing tirzepatide copies within 60 days for bulk operations and 90 days for traditional pharmacies. This timeline matters because compounded tirzepatide has been a lower-cost alternative. A 2024 analysis found average prices of $300-$500 per month for compounded versions versus $1,000+ for brand-name pens (Smith 2024).
Semaglutide Remains in Shortage, For Now
Semaglutide, the active ingredient in Ozempic and Wegovy, is still listed as in shortage. The FDA has not scheduled a similar vote for semaglutide, but the agency's recent warning letters about online semaglutide sales suggest scrutiny is increasing. Compounded semaglutide remains available from state-licensed pharmacies, though the FDA has flagged quality concerns. A 2023 investigation found that some compounded semaglutide samples contained impurities or incorrect salt forms (FDA 2023). Researchers should note that semaglutide compounding is permitted only when the drug is in shortage, a status that could change quickly.
What the Vote Means for Compounding Access
If tirzepatide compounding ends, three immediate effects are likely: 1) Patients relying on compounded tirzepatide will need to switch to brand-name pens or alternative therapies. 2) Some compounding pharmacies may shift focus to semaglutide, increasing demand pressure. 3) Regulatory enforcement will intensify, with the FDA issuing warning letters to noncompliant compounders. The agency has already found subpotent tirzepatide in some compounded formulations, as detailed in its recent testing results. These findings reinforce the FDA's rationale for tighter controls.
Ongoing GLP-1 Safety Warnings
The FDA continues to monitor adverse events linked to GLP-1 agonists. A 2024 safety communication highlighted risks of ileus, pancreatitis, and medication errors from compounded versions (FDA 2024). Compounded products may use salt forms like semaglutide sodium or semaglutide acetate, which have not been studied for safety or efficacy. The agency has received reports of dosing errors when patients transition between compounded and brand-name products. These warnings apply to both tirzepatide and semaglutide. Researchers investigating GLP-1 mechanisms should be aware that compounded formulations may introduce variables not present in approved drugs.
Who Is Affected
The panel vote primarily affects three groups: patients using compounded tirzepatide for weight loss or diabetes, compounding pharmacies that produce it, and telehealth platforms prescribing it. A 2024 survey found that 22% of GLP-1 users obtained their medication from compounding pharmacies (Jones 2024). For these individuals, the transition may involve higher costs or treatment gaps. Pharmacies face revenue loss and potential legal exposure if they continue compounding after the deadline. Telehealth companies may need to adjust their business models. Semaglutide users are not directly impacted yet, but the regulatory trajectory suggests similar restrictions could follow.
Broader Peptide Research Context
While tirzepatide and semaglutide dominate headlines, other peptides like BPC-157, MK-677, Semax, and Hexarelin remain in a different regulatory category. These compounds are not FDA-approved and are typically sold for research purposes only. The FDA's compounding rules do not apply to them, but the agency has issued warning letters to firms making therapeutic claims. A 2022 review of BPC-157 noted its experimental status and lack of human trials (Kovacs 2022). MK-677, a growth hormone secretagogue, is often mislabeled as a peptide but is actually a small molecule. Semax and Hexarelin have limited published human data. Researchers should verify the legal status of any compound before procurement.
What to Watch Next
Several developments will shape the coming months. First, the FDA's final decision on tirzepatide compounding, expected by April 2025. Second, any update to the semaglutide shortage status. Third, enforcement actions against compounders that continue producing tirzepatide after the deadline. Fourth, potential legislative responses, as some lawmakers have pushed for expanded compounding access. The FDA's ongoing investigation into compounded tirzepatide may yield further quality data. Researchers should monitor the FDA's drug shortage database and compounding policy updates for real-time changes.
We make no representation about the suitability of any compound covered here for any particular purpose.